Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors

Harm Reduction Journal

Tim Rhodes¹  Magdalena Harris¹ 

[1] Centre for Research on Drugs and Health Behaviour, London School of Hygiene and Tropical Medicine, 15-17 Tavistock Place, London, WC1H9SH, UK

关键词: Social factors;    People who inject drugs;    Treatment access;    Antiviral treatment;    Hepatitis C;   

Others  :  809905
DOI  :  10.1186/1477-7517-10-7

 received in 2012-08-06, accepted in 2013-04-13,  发布年份 2013

【 摘 要 】

Background

Evidence documents successful hepatitis C virus (HCV) treatment outcomes for people who inject drugs (PWID) and interest in HCV treatment among this population. Maximising HCV treatment for PWID can be an effective HCV preventative measure. Yet HCV treatment among PWID remains suboptimal. This review seeks to map social factors mediating HCV treatment access.

Method

We undertook a review of the social science and public health literature pertaining to HCV treatment for PWID, with a focus on barriers to treatment access, uptake and completion. Medline and Scopus databases were searched, supplemented by manual and grey literature searches. A two step search was taken, with the first step pertaining to literature on HCV treatment for PWID and the second focusing on social structural factors. In total, 596 references were screened, with 165 articles and reports selected to inform the review.

Results

Clinical and individual level barriers to HCV treatment among PWID are well evidenced. These include patient and provider concerns regarding co-morbidities, adherence, and side effect management. Social factors affecting treatment access are less well evidenced. In attempting to map these, key barriers fall into the following domains: social stigma, housing, criminalisation, health care systems, and gender. Key facilitating factors to treatment access include: combination intervention approaches encompassing social as well as biomedical interventions, low threshold access to opiate substitution therapy, and integrated delivery of multidisciplinary care.

Conclusion

Combination intervention approaches need to encompass social interventions in relation to housing, stigma reduction and systemic changes in policy and health care delivery. Future research needs to better delineate social factors affecting treatment access.

【 授权许可】

   
2013 Harris and Rhodes; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]World Health Organisation: Hepatitis C facts and figures. 2011. http://www.euro.who.int/en/what-we-do/health-topics/diseases-and-conditions/hepatitis/facts-and-figures/hepatitis-c webcite
• [2]World Health Organization: Resolution A63/15: Viral hepatitis. 63rd World Health Assembly. 2010. http://apps.who.int/gb/ebwha/pdf_files/WHA63/A63_15-en.pdf webcite
• [3]Nelson PK, et al.: Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011, 378:571-583.
• [4]Ghany M, Strader B, Thomas D, Seeff L: Diagnosis, management and treatment of HCV: An update. Hepatology 2009, 49:1335-1374.
• [5]Martin NK, et al.: Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol 2011, 54:1137-1144.
• [6]Vickerman P, Hickman M, Judd A: Modelling the impact on HCV transmission of reducing syringe sharing: London case study. Int J Epidemiol 2007, 36:396-405.
• [7]Doab A, Treloar C, Dore G: Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia. Clin Infect Dis 2005, 40:S313-S320.
• [8]Treloar C, Holt M: Drug treatment clients’ readiness for hepatitis C treatment: implications for expanding treatment services in drug and alcohol settings. Aust Health Rev 2008, 32:570.
• [9]Canfield KM, Smyth E, Batki SL: Methadone maintenance patients’ knowledge, attitudes, beliefs, and experiences concerning treatment for hepatitis C virus infection. Subs Use Misuse 2010, 45:496-514.
• [10]Grebely J, et al.: Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug Alcohol Depend 2008, 93:141-147.
• [11]Strathdee SA, et al.: Factors associated with interest in initiating treatment for hepatitis C virus (HCV) infection among young HCV-infected injection drug users. Clin Infect Dis 2005, 40:S304-S312.
• [12]Walley A, White M, Kushel M, Song Y, Tulsky JP: Knowledge of and interest in hepatitis C treatment at a methadone clinic. J Subst Abuse Treatment 2005, 28:181-187.
• [13]Bruggmann P, et al.: Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients. J Viral Hepat 2008, 15:747-752.
• [14]Jack K, Willott S, Manners J, Varnam MA, Thomson BJ: Clinical trial: a primary-care-based model for the delivery of anti-viral treatment to injecting drug users infected with hepatitis C. Aliment Pharmacol Ther 2009, 29:38-45.
• [15]Melin P, et al.: Effectiveness of chronic hepatitis C treatment in drug users in routine clinical practice: results of a prospective cohort study. Eur J Gastroenterol Hepatol 2010, 22:1050-1057.
• [16]Sylvestre DL: Treating hepatitis C virus infection in active substance users. Clin Infect Dis 2005, 40:S321-S324.
• [17]Mehta SH, et al.: Limited uptake of hepatitis C treatment among injection drug users. J Comm Health 2008, 33:126-133.
• [18]National Institute for Clinical Excellence: Technology Appraisal Guidance 75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic HCV. London: National Institute for Clinical Excellence; 2004.
• [19]Reimer J, Backmund M, Haasen C: New psychiatric and psychological aspects of diagnosis and treatment of hepatitis C and relevance for opiate dependence. Curr Opin Psychiatr 2005, 18:678-683.
• [20]Topp L: 1 client, 2 needs: Improving access to hep C services. Substance 2007, 5:14-16.
• [21]Lazarus JV, Shete PB, Eramova I, Merkinaite S, Matic S: HIV/hepatitis coinfection in eastern Europe and new pan-European approaches to hepatitis prevention and management. Int J Drug Policy 2007, 18:426-432.
• [22]Lindenburg CEA, et al.: Hepatitis C testing and treatment among active drug users in Amsterdam: results from the DUTCH-C project. Eur J Gastroenterol Hepatol 2011, 23:23-31.
• [23]Bobrova N, Sarang A, Stuikyte R, Lezhentsev K: Obstacles in provision of anti-retroviral treatment to drug users in Central and Eastern Europe and Central Asia: A regional overview. Int J Drug Policy 2007, 18:313-318.
• [24]Krusi A, Wood E, Montaner J, Kerr T: Social and structural determinants of HAART access and adherence among injection drug users. Int J Drug Policy 2010, 21:4-9.
• [25]Wolfe D, Carrieri MP, Shepard D: Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward. Lancet 2010., 376
• [26]Sarang A, Rhodes T, Sheon N: Systemic barriers to accessing HIV treatment among people who inject drugs in Russia: a qualitative study. Health Policy Plann 2012. in press
• [27]Lally MA, Montstream-Quas SA, Tanaka S, Tedeschi SK, Morrow KM: A qualitative study among injection drug using women in Rhode Island: attitudes toward testing, treatment, and vaccination for hepatitis and HIV. AIDS Patient Care STDS 2008, 22:53-64.
• [28]Treloar C, Rhodes T: The lived experience of hepatitis C and its treatment among injecting drug users: qualitative synthesis. Qual Health Res 2009, 19:1321-1334.
• [29]John-Baptiste A, et al.: Treatment of hepatitis C infection for current or former substance abusers in a community setting. J Viral Hepat 2009, 16:557-567.
• [30]Rhodes T: Risk environments and drug harms: A social science for harm reduction approach. Int J Drug Policy 2009, 20:193-201.
• [31]Harris M: Relapse to injecting drug use: A hepatitis C treatment concern. Contemp Drug Probl 2009, 39:303-326.
• [32]Hopwood M, Treloar C: The experience of interferon-based treatments for hepatitis C infection. Qual Health Res 2005, 15:635-646.
• [33]Sheppard K, Hubbert A: The patient experience of treatment for hepatitis C. Gastroenterol Nursing 2006, 29:309-315.
• [34]Treloar C, Hopwood M: “Look, I’m fit, I’m positive and I’ll be all right, thank you very much”: coping with hepatitis C treatment and unrealistic optimism. Psychol Health Med 2008, 13:360-366.
• [35]Zickmund S, et al.: Majority of patients with hepatitis C express physical, mental, and social difficulties with antiviral treatment. Eur J Gastroenterol Hepatol 2006, 18:381-388.
• [36]McNally S, Temple-Smith M: Now, later or never? Challenges associated with hepatitis C treatment. Aust N Z J Public Health 2006, 30:422-427.
• [37]Schackman BR, Teixeira PA, Beeder AB: Offers of hepatitis C care do not lead to treatment. J Urban Health 2007, 84:455-458.
• [38]Neale J: Homelessness, drug use and hepatitis C: a complex problem explored within the context of social exclusion. Int J Drug Policy 2008, 19:429-435.
• [39]Treloar C, Newland J, Rance J, Hopwood M: Uptake and delivery of hepatitis C treatment in opiate substitution treatment: perceptions of clients and health professionals. J Viral Hep 2010, 17:839-844.
• [40]Swan D, et al.: Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: a qualitative exploration. AIDS Patient Care STDS 2010, 24:753-762.
• [41]Coppola AG, et al.: Hepatitis C knowledge among primary care residents: is our teaching adequate for the times? Am J Gastroenterol 2004, 99:1720-1725.
• [42]Gupta L, Shah S, Ward JE: Educational and health service needs of Australian general practitioners in managing hepatitis C. J Gastroenterol Hepatol 2006, 21:694-699.
• [43]Treloar C, et al.: Factors associated with hepatitis C knowledge among a sample of treatment naive people who inject drugs. Drug Alcohol Depend 2011, 116:52-56.
• [44]Strauss S, et al.: Barriers and facilitators to undergoing hepatitis C virus (HCV) testing through drug treatment programs. J Drug Is 2008, 38:1161.
• [45]Harris M, Rhodes T, Martin A: Taming systems to create enabling environments for HCV treatment: negotiating trust in the drug and alcohol setting. Soc Sci Med 2013, 83:19-26.
• [46]Fraenkel L, McGraw S, Wongcharatrawee S, Garcia-Tsao G: Patients’ experiences related to anti-viral treatment for hepatitis C. Patient Educ Counsel 2006, 62:148-155.
• [47]Harris M: Injecting, infection, illness: abjection and hepatitis C stigma. Body Soc 2009, 15:33-51.
• [48]Hopwood M, Treloar C, Bryant J: HCV and injecting-related discrimination in New South Wales, Australia. Drugs Educ, Prev Policy 2006, 13:61-75.
• [49]Grebely J, et al.: Factors associated with specialist assessment and treatment for hepatitis C virus infection in New South Wales, Australia. J Viral Hep 2011, 18:104-116.
• [50]Krook AL, Stokka D, Heger B, Nygaard E: Hepatitis C treatment of opioid dependants receiving maintenance treatment: results of a Norwegian pilot study. Eur Addict Res 2007, 13:216-221.
• [51]Alvarez-Uria G, Day JN, Nasir AJ, Russell SK, Vilar FJ: Factors associated with treatment failure of patients with psychiatric diseases and injecting drug users in the treatment of genotype 2 or 3 hepatitis C chronic infection. Liver Int 2009, 29:1051-1055.
• [52]Scott J, et al.: Hepatitis C virus is infrequently evaluated and treated in an urban HIV clinic population. AIDS Patient Care STDS 2009, 23:924-929.
• [53]Anand BS, et al.: Alcohol use and treatment of hepatitis C virus: results of a national multicenter study. Gastroenterology 2006, 130:1607-1616.
• [54]Gidding HF, et al.: Predictors of deferral of treatment for hepatitis C infection in Australian clinics. Med J Austr 2011, 194:398-402.
• [55]Dalgard O: Follow-Up Studies of Treatment for Hepatitis C Virus Infection among Injection Drug Users. Clin Infect Dis 2005, 40:S336-S338.
• [56]Grebely J, et al.: Reinfection with hepatitis C virus following sustained virological response in injection drug users. JGastroenterol Hepatol 2010, 25:1281-1284.
• [57]Backmund M, Reimer J, Meyer K, Gerlach JT, Zachoval R: Hepatitis C virus infection and injection drug users: Prevention, risk factors, and treatment. Clin Infect Dis 2005, 40:S330-S335.
• [58]Backmund M, Meyer K, Edlin BR: Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. Clin Infect Dis 2004, 39:1540-1543.
• [59]Grebely J, et al.: Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. Int J Drug Policy 2007, 18:437-443.
• [60]Wilkinson M, et al.: Community-based treatment for chronic hepatitis C in drug users: high rates of compliance with therapy despite ongoing drug use. Aliment Pharmacol Ther 2009, 29:29-37.
• [61]World Health Organisation Regional Office for Europe: Barriers and facilitators to hepatitis C treatment for people who inject drugs: A qualitative study. Copenhagen: World Health Organisation Regional Office for Europe; 2012.
• [62]Gardenier D, Wisnivesky J, McGinn LK, Kronish IM, McGinn TG: Hepatitis C treatment completion in individuals with psychiatric comorbidity and depression. Gastroenterol Nursing 2011, 34:102-106.
• [63]Schaefer M, et al.: Hepatitis C treatment in “difficult-to-treat” psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology 2007, 46:991-998.
• [64]Murray MCM, et al.: Hepatitis C virus treatment rates and outcomes in HIV/hepatitis C virus co-infected individuals at an urban HIV clinic. Eur J Gastroenterol Hepatol 2011, 23:45-50.
• [65]Novick DM, Kreek MJ: Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients. Addiction 2008, 103:905-918.
• [66]Taylor LE, et al.: Treatment for hepatitis C virus genotype 1 infection in HIV-infected individuals on methadone maintenance therapy. Drug Al Depend 2011, 116:233-237.
• [67]Bova C, Ogawa LF, Sullivan-Bolyai S: Hepatitis C Treatment Experiences and Decision Making Among Patients Living With HIV Infection. J Assoc Nur AIDS Care 2010, 21:63-74.
• [68]Friedland G: Infectious disease comorbidities adversely affecting substance users with HIV: Hepatitis C and tuberculosis. J Acquir Immune Defic Syndr 2010, 55:S37-S42.
• [69]Khalsa JH, Vocci F: Clinical Management of Drug Addicts Infected with Human Immunodeficiency Virus and Hepatitis C Virus. J Addict Dis 2008, 27:1-10.
• [70]Fischer B, Haydon E, Rehm J, Krajden M, Reimer J: Injection drug use and the hepatitis C virus: Considerations for a targeted treatment approach - The case study of Canada. J Urban Health-Bulletin New York Acad Med 2004, 81:428-447.
• [71]Dieperink E, Willenbring M, Ho SB: Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review. Am J Psychiatr 2000, 157:867.
• [72]Edlin BR, et al.: Overcoming Barriers to Prevention. Care, and Treatment of Hepatitis C in Illicit Drug Users. Clin Infect Dis 2005, 40:S276-S285.
• [73]Day C, Ross J, Dolan K: Hepatitis C-related discrimination among heroin users in Sydney: drug user or hepatitis C discrimination? Drug Al Rev 2003, 22:317-321.
• [74]Cullen W, Kelly Y, Stanley J, Langton D, Bury G: Experience of hepatitis C among current or former heroin users attending general practice. Irish Med J 2005, 98:73-74.
• [75]McGowan CE, Fried MW: Barriers to hepatitis C treatment. Liver Int 2012, 32:151-156.
• [76]Khaw F-M, Stobbart L, Murtagh MJ: ‘I just keep thinking I haven’t got it because I’m not yellow’: a qualitative study of the factors that influence the uptake of Hepatitis C testing by prisoners. BMC Public Health 2007, 7:98. BioMed Central Full Text
• [77]Temple-Smith M, et al.: Gender differences in seeking care for hepatitis C in Australia. J Substance Use 2007, 12:59-70.
• [78]Astell-Burt T, Flowerdew R, Boyle P, Dillon J: Does geographic access to primary healthcare influence the detection of hepatitis C? Soc Sci Med 2011, 72:1472-1481.
• [79]Hopwood M, Nakamura T, Treloar C: Disclosing hepatitis C infection within everyday contexts: Implications for accessing support and healthcare. J Health Psychol 2010, 15:811-818.
• [80]Klitzman RL, et al.: Intricacies and inter-relationships between HIV disclosure and HAART: A qualitative study. AIDS Care 2004, 16:628-640.
• [81]Vervoort SC, Borleffs JC, Hoepelman AI, Grypdonck MH: Adherence in antiretroviral therapy: A review of qualitative studies. AIDS 2007, 21:271-281.
• [82]Richmond J, Dunning P, Desmond P: Hepatitis C: A medical and social diagnosis. Austr Nursing J 2004, 12:23-25.
• [83]Tindal C, Cook K, Foster N: Theorising stigma and the experiences of injecting drug users in Australia. Austr J Primary Health 2010, 16:119-125.
• [84]Cheung RC, Hanson AK, Maganti K, Keeffe EB, Matsui SM: Viral hepatitis and other infectious diseases in a homeless population. J Clin Gastroenterol 2002, 34:476-480.
• [85]Hickman M, et al.: Hepatitis C virus (HCV) prevalence, and injecting risk behaviour in multiple sites in England in 2004. J Viral Hep 2007, 14:645-652.
• [86]Kim C, et al.: Unstable housing and hepatitis C incidence among injection drug users in a Canadian setting. BMC Public Health 2009, 9:270. BioMed Central Full Text
• [87]Stein JA, Nyamathi A: Correlates of hepatitis C virus infection in homeless men: a latent variable approach. Drug Al Depend 2004, 75:89-95.
• [88]Cooper CL: Obstacles to successful HCV treatment in substance addicted patients. J Addict Dis 2008, 27:61-68.
• [89]Grebely J, et al.: Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users. J Gastroenterol Hepatol 2007, 22:1519-1525.
• [90]Central and Eastern European Harm Reduction Network: Hepatitis C among injecting drug users in the new EU member states and neighboring countries: situation, guidelines and recommendations. Lithuania: Central and Eastern European Harm Reduction Network; 2007.
• [91]Monnet E, et al.: Place of residence and distance to medical care influence the diagnosis of hepatitis C: a population-based study. J Hepatol 2006, 44:499-506.
• [92]Monnet E, et al.: Socioeconomic context, distance to primary care and detection of hepatitis C: a French population-based study. Soc Sci Med 2008, 66:1046-1056.
• [93]Harris KA, Arnsten JH, Litwin AH: Successful integration of hepatitis C evaluation and treatment services with methadone maintenance. J Addict Med 2010, 4:20-26.
• [94]Roux P, et al.: The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study. Addiction 2008, 103:1828-1836.
• [95]Uhlmann S, et al.: Methadone maintenance therapy promotes initiation of antiretroviral therapy among injection drug users. Addiction 2010, 105:907-913.
• [96]Batey RG, Jones T, McAllister C: Prisons and HCV: a review and a report on an experience in New South Wales Australia. Int J Prisoner Health 2008, 4:156-163.
• [97]Hunt DR, Saab S: Viral hepatitis in incarcerated adults: a medical and public health concern. Am J Gastroenterol 2009, 104:1024-1031.
• [98]Remy AJ, et al.: Treatment for hepatitis C in jailhouses is doable and successful: definitive data of first national French study (POPHEC). Heroin Addiction Related Clin Prob 2006, 8:47-49.
• [99]Brunsden A: Hepatitis C in prisons: evolving toward decency through adequate medical care and public health reform. UCLA Law Rev 2006, 54:465-507.
• [100]Farley J, et al.: Feasibility and outcome of HCV treatment in a Canadian federal prison population. Am J Public Health 2005, 95:1737-1739.
• [101]Van Thiel DH, Anantharaju A, Creech S: Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse. Am J Gastroenterol 2003, 98:2281-2288.
• [102]Brener L, Von Hippel W, Kippax S: Prejudice among health care workers toward IDUs with hepatitis C: does greater contact lead to less prejudice? Int J Drug Policy 2007, 18:381-387.
• [103]Paterson BL, Backmund M, Hirsch G, Yim C: The depiction of stigmatization in research about hepatitis C. Int J Drug Policy 2007, 18:364-373.
• [104]Hopwood M, Treloar C: The drugs that dare not speak their name: injecting and other illicit drug use during treatment for hepatitis C infection. Int J Drug Policy 2007, 18:374-380.
• [105]Treloar C, Newland J, Harris M, Deacon R, Maher L: A diagnosis of hepatitis C - insights from a study on patient’s experiences. Austr Family Phys 2010, 39:589-592.
• [106]Giordano C, Druyts E, Garber G, Cooper C: Evaluation of immigration status, race and language barriers on chronic HCV infection management and treatment outcomes. Eur J Gastroenterol Hepatol 2009, 21:963.
• [107]Gifford S, O’Brien M, Bammer G, Banwell C, Stoove M: Australian women’s experiences of living with hepatitis C virus: results from a cross-sectional survey. Eur J Gastroenterol Hepatol 2003, 18:841-850.
• [108]Broers B, et al.: Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C. J Hepatol 2005, 42:323-328.
• [109]Khokhar OS, Lewis JH: Reasons why patients infected with chronic hepatitis C virus choose to defer treatment: do they alter their decision with time? Digestive Dis Sci 2007, 52:1168-1176.
• [110]Lowry DJ, Ryan JD, Ullah N, Kelleher TB, Crowe J: Hepatitis C management: the challenge of dropout associated with male sex and injection drug use. Eur J Gastroenterol Hepatol 2011, 23:32-40.
• [111]Campbell N: Using women: Gender, drug policy and social justice. New York, London: Routledge; 2000.
• [112]Kurtz SP, Surratt HL, Kiley MC, Inciardi JA: Barriers to health and social services for street-based sex workers. J Health Care Poor Underserved 2005, 16:345-361.
• [113]Bourgois P, Prince B, Moss A: The everyday violence of hepatitis C among young women who inject drugs in San Francisco. Hum Organ 2004, 63:253.
• [114]Hall CS, Charlebois ED, Hahn JA, Moss AR, Bangsberg DR: Hepatitis C virus infection in San Francisco’s HIV-infected urban poor. J Gen Int Med 2004, 19:357-365.
• [115]Almasio PL, et al.: Recommendations for the prevention, diagnosis, and treatment of chronic hepatitis b and c in special population groups (migrants, intravenous drug users and prison inmates). Digest Liver Dis 2011, 43:589-595.
• [116]World Health Organisation, UN Office of Drugs and Crime & UNAIDS: Technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users. Geneva: World Health Organisation, UN Office of Drugs and Crime & UNAIDS; 2009.
• [117]Litwin AH, et al.: Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. J Subs Abuse Treat 2009, 37:32-40.
• [118]Sylvestre DL: Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend 2002, 67:117-123.
• [119]Zanini B, Lanzini A: Antiviral treatment for chronic hepatitis C in illicit drug users: a systematic review. Antiviral Ther 2009, 14:467-479.
• [120]Hagan H, Pouget E, Des Jarlais D: A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. J Infect Dis 2011, 204:74-83.
• [121]Turner K, et al.: The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction 2011, 106:1978-1988.
• [122]Harris M, Rhodes T: Methadone diversion as a protective strategy: the harm reduction potential of ‘generous constraints’. Int J Drug Policy 2013. http://www.ncbi.nlm.nih.gov/pubmed/23199896 webcite
• [123]Moussalli J, et al.: Factors to improve the management of hepatitis C in drug users: an observational study in an addiction centre. Gastroenterol Res Pract 2010, 4. http://www.ncbi.nlm.nih.gov/pubmed/20811482 webcite
• [124]Cournot M, et al.: Management of hepatitis C in active drugs users: experience of an addiction care hepatology unit. Gastroenterol Clin Biol 2004, 28:533-539.
• [125]Mason S, Watts A, Sheils S, Koorey D: Improving access to HCV treatment: external jugular venepuncture can overcome problems with difficult venous access. Int J Drug Policy 2007, 18:433-436.
• [126]Hallinan R, Byrne A, Dore G: Harm reduction, hepatitis C and opioid pharmacotherapy: an opportunity for integrated hepatitis C virus-specific harm reduction. Drug Al Rev 2007, 26:437-443.
• [127]Sylvestre D, Zweben J: Integrating HCV services for drug users: a model to improve engagement and outcomes. Int J Drug Policy 2007, 18:406-410.
• [128]Strauss S, Munoz-Plaza C, Rosedale M, Rindskopf D, Lunievicz J: Enhancing drug treatment program staff’s self-efficacy to support patients’ HCV needs. J Soc Work Prac Addict 2011, 11:254-269.
• [129]Arora A, et al.: Outcomes of treatment for hepatitis C virus infection by primary care providers. New England J Med 2011, 364(2199):2199-2207.
• [130]Grebely J, et al.: Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support. Eur J Gastroenterol Hepatol 2010, 22:270-277.
• [131]Norman J, et al.: The acceptability and feasibility of peer worker support role in community based HCV treatment for injecting drug users. Harm Red J 2008, 5:5. BioMed Central Full Text
• [132]Rance J, Newland J, Hopwood M, Treloar C: The politics of place(ment): problematising the provision of hepatitis C treatment within opiate substitution clinics. Soc Sci Med 2012, 74:245-253.
• [133]Treloar CJ, Fraser SM: Hepatitis C treatment in pharmacotherapy services: increasing treatment uptake needs a critical view. Drug Al Rev 2009, 28:436-440.
• [134]Brener L, Treloar C: Alcohol and other drug treatment experiences of hepatitis C-positive and negative clients: implications for hepatitis C treatment. Aust Health Rev 2009, 33:100-106.
• [135]Strathdee SA, et al.: HIV and risk environment for injecting drug users: the past, present, and future. Lancet 2010, 376:268-284.